Osteoclast inhibitors for knee conditions
View Patent ↗Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, such as zoledronic acid, can be used to treat or alleviate pain or related conditions.
1. A method of treating moderate to severe knee pain comprising administering zoledronic acid to a person suffering from moderate to severe knee pain, wherein the person is selected for having a pain intensity of 5 or greater measured using the 0-10 numerical rating scale (NRS) or 5 cm or greater using the 10 cm visual analog scale (VAS), and having osteoarthritis and a bone marrow lesion.
2. The method of claim 1 , wherein the person suffering from moderate to severe knee pain has a normal joint space in the knee, with OARSI Grade 0, or Kellgren and Lawrence Grades 0 or 1, joint space narrowing.
3. The method of claim 1 , wherein the zoledronic acid is administered orally or intravenously.
4. The method of claim 1 , wherein the zoledronic acid is administered daily, every other day, every three days, weekly, biweekly, monthly, bi-monthly, yearly or every two years.
5. The method of claim 1 , wherein the zoledronic acid is orally administered to the person in a disodium salt form.
6. The method of claim 5 , wherein the person experiences a reduction in pain intensity of at least about 1 cm, using the 10 cm VAS, as compared to a placebo.
7. The method of claim 5 , wherein the person experiences a reduction in pain intensity of at least about 5 cm, using the 10 cm VAS, as compared to a placebo.
8. The method of claim 5 , wherein the person experiences a reduction in pain intensity of at least about 1.5 cm, using the 10 cm VAS, as compared to a placebo.
9. The method of claim 1 , wherein the person experiences significant pain relief during at least part of the time from about 3 hours to about 2 weeks after the zoledronic acid is administered to the person.
10. The method of claim 1 , wherein the person experiences pain relief for at least about one week after the zoledronic acid is administered to the person.
11. The method of claim 1 , wherein administering zoledronic acid reduces the use of a non-zoledronic acid pain medication by at least about 15% as compared to the use of the non-zoledronic acid pain medication without administration of the zoledronic acid.
12. The method of claim 1 , wherein administering zoledronic acid reduces the use of a non-zoledronic acid pain medication by at least about 80% as compared to the use of the non-zoledronic acid pain medication prior to administration of the zoledronic acid.
13. The method of claim 1 , wherein about 5 mg to about 500 mg of the zoledronic acid is administered.
14. The method of claim 13 , wherein about 40 mg to about 300 mg of the zoledronic acid is orally administered.
15. The method of claim 14 , wherein about 40 mg to about 60 mg of the zoledronic acid is orally administered weekly for about 2 to about 6 weeks.
16. The method of claim 5 , wherein about 50 mg to about 60 mg of the disodium salt form of zoledronic acid is orally administered.
17. The method of claim 16 , the person experience significant pain relief that lasts for about 3 days to about 2 weeks after orally administering zoledronic acid in the disodium salt form.
18. A method of treating moderate knee pain comprising administering zoledronic acid to a person suffering from moderate knee pain, wherein the person is selected for having a pain intensity of about 5 to about 7 measured using the 0-10 NRS or about 5 cm to about 7 cm using the 10 cm VAS, and having osteoarthritis and a bone marrow lesion.
19. The method of claim 18 , wherein the person experiences a reduction in pain intensity of at least about 0.8, using the 0-10 NRS, as compared to a placebo.
20. The method of claim 18 , wherein the person experiences a reduction in pain intensity of at least about 1.5, using the 0-10 NRS, as compared to a placebo.
21. The method of claim 18 , wherein the person experiences significant pain relief during at least part of the time from about 6 hours to about 3 weeks after the zoledronic acid is administered to the person.
22. The method of claim 18 , wherein administering zoledronic acid reduces the use of a non-zoledronic acid pain medication by at least about 35% as compared to the use of the non-zoledronic acid pain medication prior to administration of the zoledronic acid.
23. The method of claim 18 , wherein about 40 mg to about 500 mg of the zoledronic acid is orally administered.
24. A method of treating severe knee pain comprising administering zoledronic acid to a person suffering from severe knee pain, wherein the person is selected for having a pain intensity of about 7 or greater measured using the 0-10 NRS or about 7 cm or greater using the 10 cm VAS, and having osteoarthritis and a bone marrow lesion.
25. The method of claim 24 , wherein the person experiences a reduction in pain intensity of at least about 1.5, using the 0-10 NRS, as compared to a placebo.
26. The method of claim 24 , wherein the person experiences a reduction in pain intensity of at least about 5, using the 0-10 NRS, as compared to a placebo.
27. The method of claim 24 , wherein the person experiences significant pain relief during at least part of the time from about 6 hours to about 2 weeks after the zoledronic acid is administered to the person.
28. The method of claim 24 , wherein administering zoledronic acid reduces the use of a non-zoledronic acid pain medication by at least about 25% as compared to the use of the non-zoledronic acid pain medication prior to administration of the zoledronic acid.
29. The method of claim 24 , wherein about 150 mg to about 500 mg of the zoledronic acid is orally administered.